Literature DB >> 23168260

JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.

Frédérick A Mallette1, Stéphane Richard.   

Abstract

Senescence is a cellular response preventing tumorigenesis. The Ras oncogene is frequently activated or mutated in human cancers, but Ras activation is insufficient to transform primary cells. In a search for cooperating oncogenes, we identify the lysine demethylase JMJD2A/KDM4A. We show that JMJD2A functions as a negative regulator of Ras-induced senescence and collaborates with oncogenic Ras to promote cellular transformation by negatively regulating the p53 pathway. We find CHD5, a known tumor suppressor regulating p53 activity, as a target of JMJD2A. The expression of JMJD2A inhibits Ras-mediated CHD5 induction leading to a reduced activity of the p53 pathway. In addition, we show that JMJD2A is overexpressed in mouse and human lung cancers. Depletion of JMJD2A in the human lung cancer cell line A549 bearing an activated K-Ras allele triggers senescence. We propose that JMJD2A is an oncogene that represents a target for Ras-expressing tumors.
Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168260     DOI: 10.1016/j.celrep.2012.09.033

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  52 in total

1.  Histone demethylases and their roles in cancer epigenetics.

Authors:  Alexandra D'Oto; Qing-Wu Tian; Andrew M Davidoff; Jun Yang
Journal:  J Med Oncol Ther       Date:  2016

2.  Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.

Authors:  Roselyne M Labbé; Andreana Holowatyj; Zeng-Quan Yang
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

Review 3.  Architects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromes.

Authors:  Wangzhi Li; Alea A Mills
Journal:  Epigenomics       Date:  2014       Impact factor: 4.778

4.  Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.

Authors:  Xiaojiang Li; Shanshan Dong
Journal:  Med Oncol       Date:  2015-01-31       Impact factor: 3.064

Review 5.  The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.

Authors:  Alea A Mills
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 6.  Role of CHD5 in human cancers: 10 years later.

Authors:  Venkatadri Kolla; Tiangang Zhuang; Mayumi Higashi; Koumudi Naraparaju; Garrett M Brodeur
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

7.  KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.

Authors:  Ling-Yu Wang; Chiu-Lien Hung; Yun-Ru Chen; Joy C Yang; Junjian Wang; Mel Campbell; Yoshihiro Izumiya; Hong-Wu Chen; Wen-Ching Wang; David K Ann; Hsing-Jien Kung
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

8.  Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.

Authors:  Tae-Dong Kim; Fang Jin; Sook Shin; Sangphil Oh; Stan A Lightfoot; Joseph P Grande; Aaron J Johnson; Jan M van Deursen; Jonathan D Wren; Ralf Janknecht
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

9.  KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors.

Authors:  Joshua C Black; Amity L Manning; Capucine Van Rechem; Jaegil Kim; Brendon Ladd; Juok Cho; Cristiana M Pineda; Nancy Murphy; Danette L Daniels; Cristina Montagna; Peter W Lewis; Kimberly Glass; C David Allis; Nicholas J Dyson; Gad Getz; Johnathan R Whetstine
Journal:  Cell       Date:  2013-07-18       Impact factor: 41.582

10.  Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.

Authors:  Junjian Wang; Haibin Wang; Ling-Yu Wang; Demin Cai; Zhijian Duan; Yanhong Zhang; Peng Chen; June X Zou; Jianzhen Xu; Xinbin Chen; Hsing-Jien Kung; Hong-Wu Chen
Journal:  Cell Death Differ       Date:  2016-09-09       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.